Edition:
United Kingdom

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

10.70EUR
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
€10.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
69,350
52-wk High
€15.00
52-wk Low
€10.54

Chart for

About

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The... (more)

Overall

Beta: --
Market Cap(Mil.): €473.27
Shares Outstanding(Mil.): 44.65
Dividend: --
Yield (%): --

Financials

  BCART.BR Industry Sector
P/E (TTM): -- 32.18 33.63
EPS (TTM): -1.16 -- --
ROI: -48.76 13.76 15.02
ROE: -60.67 16.50 16.60

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

29 Nov 2018

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

29 Nov 2018

Biocartis partners with AstraZeneca on lung cancer diagnostics

Nov 29 Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

29 Nov 2018

Earnings vs. Estimates